Eagle Pharmaceuticals announced today that its dantrolene sodium injectable suspension (brand name Ryanodex) has received a patent for the treatment of exertional heat stroke, which will provide coverage through 2023. Patent ‘460 brings the company’s IP surrounding Ryanodex to four issued patents. As the patent coverage surrounding the company’s best-in-class formulation solidifies, Eagle will initiate…